# EDGAR Filing Document

**Accession Number:** 0001684144
**File Stem:** 0001654954-25-006839
**Filing Date:** 2025-6
**Character Count:** 6720
**Document Hash:** 1be5fb980f22aa1a446d68a8974a21a5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-25-006839.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0001654954-25-006839

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250610

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zomedica Corp.
- **CENTRAL INDEX KEY:** 0001684144
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38298
- **FILM NUMBER:** 251040157

**BUSINESS ADDRESS:**
- **STREET 1:** 100 PHOENIX DRIVE
- **STREET 2:** SUITE 125
- **CITY:** ANN ARBOR
- **STATE:** MI
- **ZIP:** 48108
- **BUSINESS PHONE:** (734) 369-2555

**MAIL ADDRESS:**
- **STREET 1:** 100 PHOENIX DRIVE
- **STREET 2:** SUITE 125
- **CITY:** ANN ARBOR
- **STATE:** MI
- **ZIP:** 48108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zomedica Pharmaceuticals Corp.
- **DATE OF NAME CHANGE:** 20160908

?xml version='1.0' encoding='ASCII'? zom_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): <u>June 10, 2025</u>**

---

| |
|:---|
| **Zomedica Corp.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Alberta, Canada**  | **001-38298**  | **N/A** |
| (State or other jurisdiction <br>of incorporation) | (Commission <br>File Number)  | (IRS Employer <br>Identification Number) |

---

---

| | |
|:---|:---|
| **1101 Technology Drive, Suite 100, Ann Arbor, Michigan**  | **48108** |
| (Address of principal executive offices)  | (Zip Code) |

---

Registrant's telephone number, including area code: **<u>(734) 369-2555</u>**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Shares, without par value | ZOMDF | OTCQB |

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

An annual meeting of our shareholders was held on June 10, 2025 (the "Annual Meeting"). At the Annual Meeting, our shareholders voted on each of the following three matters:

---

| |
|:---|
| Proposal 1: Election of eight directors, each for a one-year term; |
| Proposal 2: Ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm for 2025; and |
| Proposal 3: An advisory vote to approve the compensation of our named executive officers as described in our management information circular and proxy statement for the Annual Meeting. |

---

According to the final vote, the Company's stockholders approved proposals 1 and 2 and did not approve proposal 3.

The final vote results for each of these four matters is set forth below.

**Proposal 1: Election of Eight Directors**

---

| | | | |
|:---|:---|:---|:---|
|  | **For** | **Withheld** | **Broker Non-Vote** |
| Jeffrey Rowe | 95792896 | 75566044 | 208728775 |
| Robert Cohen | 100785327 | 70573613 | 208728775 |
| Chris Macleod | 95850378 | 75508561 | 208728775 |
| Pam Nichols | 103110023 | 68248916 | 208728775 |
| Johnny D. Powers | 107607577 | 63751362 | 208728775 |
| Sean Whelan | 96868224 | 74490716 | 208728775 |
| Rodney Williams | 95228838 | 76130102 | 208728775 |
| Larry Heaton | 85282021 | 86076919 | 208728775 |

---

Accordingly, stockholders elected all director nominees to hold office for terms expiring at the Company's 2026 annual meeting of stockholders.

**Proposal 2: Ratification of Independent Auditors**

---

| | |
|:---|:---|
| For: | 310,647,377  |
| Withheld: | 69,440,338  |

---

Accordingly, stockholders ratified the appointment of Grant Thornton, LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2025.

**Proposal 3: Advisory Vote on the Company's Executive Compensation**

The votes cast on the advisory vote to approve the compensation of our named executive officers disclosed in our management information circular and proxy statement for the Annual Meeting were as follows:

---

| | |
|:---|:---|
| For: | 56,659,992  |
| Against: | 82,373,446  |
| Abstain: | 32,325,502 |
| Broker Non-Vote | 208,728,775  |

---

Accordingly, stockholders failed to approve, on a non-binding advisory basis, the compensation paid to our named executive officers.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit Number | Description |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

2<br>

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Zomedica Corp. | Zomedica Corp. |
|  | By: | /s/ Karen DeHaan-Fullerton |
|  |  | Karen DeHaan-Fullerton |
|  |  | General Counsel and Corporate Secretary |
| Date: June 11, 2025 |  |  |

---

3<br>